Clinical Trials Logo

Clinical Trial Summary

This study is a 2-part study.

Part A is a single-dose, open-label study design to determine the PK, safety and tolerability of 5 μg TRK-820 oral administration in subjects with end-stage renal disease (ESRD) who require hemodialysis.

Part B is a multiple dose, open-label study design to determine the PK, PD, safety and tolerability of multiple doses in subjects with ESRD who require hemodialysis with refractory uremic pruritus (UP). Each subject will receive 3 doses of TRK-820 (2.5, 5 and 10 μg).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03002233
Study type Interventional
Source Toray Industries, Inc
Contact
Status Completed
Phase Phase 1
Start date November 2016
Completion date July 2017

See also
  Status Clinical Trial Phase
Recruiting NCT04728984 - A Multi-site Bridging Study of Nalfurafine Hydrochloride Orally Disintegrating Tablet Phase 3
Completed NCT02143973 - Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Terminated NCT01660243 - Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis Phase 2
Recruiting NCT04470154 - A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis Phase 2
Completed NCT03998163 - CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT04393675 - Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients Phase 1/Phase 2
Completed NCT03576235 - Safety and Efficacy of PG102P for Uremic Pruritus in HD Patients N/A
Completed NCT02858726 - Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 2/Phase 3
Completed NCT02143648 - Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus Phase 2/Phase 3
Completed NCT00494975 - The Effect of Phototherapy on Pruritus of Patients With Chronic Kidney Disease N/A
Completed NCT03758079 - Comparison of Gabapentin With Doxepin in the Management of Uremic Pruritus Phase 4
Completed NCT02229929 - Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus Phase 2
Recruiting NCT04639674 - AST-120 in Hemodialysis Patients With Uremic Pruritus N/A
Completed NCT03636269 - CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus Phase 3
Recruiting NCT04711603 - A Phase III Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 3
Completed NCT02696499 - Treatment of Uremic Pruritus With PA101B Phase 2
Completed NCT03422653 - A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1) Phase 3
Completed NCT03802617 - A Clinical Study of MR13A9 in Hemodialysis Patients With Pruritus. Phase 2
Not yet recruiting NCT00793156 - A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of Oral Nalfurafine HCl (AC-820)in Subjects on Hemodialysis With Uremic Pruritus (Renal Itch) Phase 3
Not yet recruiting NCT04650750 - The Treatment Effect of Chinese Medicine Formula on Uremic Pruritus Early Phase 1